<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3001233190
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BOSENTOR 125 mg Film-Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BOSENTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6115.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Genvion Corporation" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Genvion Corporation
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pharma Pharmaceutical Industries (PPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C02KX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bosentor (bosentan) tablets are prescribed for the treatment of pulmonary arterial hypertension (high</p><p>blood pressure in the blood vessels between the heart and the lungs).</p><p>Bosentor reduces abnormally high blood pressure by relaxing these blood vessels. Bosentor tablets</p><p>belong to the class of medicines known as endothelin receptor antagonists.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Tests your doctor will do before treatment:</strong></p><p>&bull; a blood test for liver function;</p><p>&bull; a blood test for anemia (reduction in red blood cells);</p><p>&bull; a pregnancy test.</p><p><strong>When it should not be used:</strong></p><p>Do not use Bosentor if you:</p><p>&bull; are hypersensitive (allergic) to bosentan or any other ingredients in the tablet (<strong>See What the</strong></p><p><strong>nonmedicinal ingredients are</strong>);</p><p>&bull; have liver problems;</p><p>&bull; are pregnant or planning to become pregnant (hormonal contraceptives alone are not effective</p><p>when you take Bosentor);</p><p>&bull; are a woman of childbearing age and not using adequate contraceptive methods;</p><p>&bull; are being treated with cyclosporine A, or glyburide.</p><p>Tell your doctor immediately if you are pregnant or plan to become pregnant in the near future. This</p><p>is because Bosentor may harm your unborn baby and you must not take Bosentor if you are pregnant.</p><p>You must also not become pregnant while taking Bosentor. If you are a woman of childbearing age,</p><p>your doctor or gynecologist will advise you about adequate contraceptive methods while taking</p><p>Bosentor. Because Bosentor may make hormonal contraception (e.g., oral, injection, implant or skin</p><p>patches) ineffective, this method on its own is not reliable. Therefore, if you use hormonal</p><p>contraceptives you must also use a barrier method (e.g., female condom, diaphragm, contraceptive</p><p>sponge or your partner must also use a condom). Monthly pregnancy tests are recommended while</p><p>you are taking Bosentor and you are of childbearing age.</p><p>Tell your doctor immediately if you are breastfeeding. You are advised to stop breastfeeding if Bosentor</p><p>is prescribed for you because it is not known if this drug passes into the milk in women who are taking</p><p>Bosentor.</p><p>If you feel dizzy while taking Bosentor, do not drive or operate any tools or machines.</p><p>Bosentor is not recommended for children.</p><p><strong>&nbsp;</strong></p><p><strong>WARNINGS AND PRECAUTIONS</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Warnings and Precautions</p><p>Before you use BOSENTOR talk to your doctor or pharmacist if you are:</p><p>&bull; known to have liver problems;</p><p>&bull; pregnant or thinking of becoming pregnant;</p><p>&bull; a woman of childbearing age and not using adequate contraceptive methods;</p><p>&bull; breastfeeding;</p><p>&bull; hypersensitive (allergic) to bosentan or any other ingredients of BOSENTOR</p></td></tr></tbody></table><p>Before starting Bosentor treatment, tell your doctor and your pharmacist if you are taking or have</p><p>recently taken any other medicines, even those you have bought yourself. It is especially important</p><p>to tell your doctor if you are taking:</p><p>&bull; hormonal contraceptives (as these may not be effective as the sole method of contraception when</p><p>you take Bosentor);</p><p>&bull; glyburide (for diabetes);</p><p>&bull; cyclosporine A (a medicine used after transplants and to treat psoriasis), or any other drugs used</p><p>to prevent rejection of transplanted organs;</p><p>&bull; fluconazole (to treat fungal infections);</p><p>&bull; rifampicin (to treat tuberculosis).</p><p><strong>Tests during treatment:</strong></p><p>Some patients taking Bosentor were found to have abnormal liver function values (increase in liver</p><p>enzymes) and some patients developed anemia (reduction in red blood cells). Because these findings</p><p>may not cause symptoms you can feel or observe yourself, your doctor will do regular blood tests to</p><p>assess any changes in your liver function and hemoglobin level.</p><p><strong>Liver function:</strong></p><p>This blood test will be done:</p><p>&bull; Every month or more frequently, if needed.</p><p>If you develop abnormal liver function, your doctor may decide to reduce your dose or stop treatment</p><p>with Bosentor. When your blood test results for liver function return to normal, your doctor may decide</p><p>to restart treatment with Bosentor.</p><p><strong>Anemia:</strong></p><p>This blood test will be done:</p><p>&bull; after 1 month and after 3 months of treatment;</p><p>&bull; every 3 months during treatment thereafter.</p><p>If you develop anemia, your doctor may decide to perform further tests to investigate the cause.</p><p>Your regular blood tests, both for liver function and anemia, are an important part of your treatment.</p><p>We suggest you write in a diary the date of your most recent test and also that of your next test (ask</p><p>your doctor for the date) to help you remember when your next test is due.</p><p>Pregnancy tests for women of childbearing age:</p><p>Due to the risk of failure of hormonal contraception when taking Bosentor and the risk in patients</p><p>with pulmonary hypertension of rapid and severe deterioration of the disease, monthly pregnancy</p><p>tests are recommended before and during treatment with Bosentor.</p><p><strong>&nbsp;</strong></p><p><strong>INTERACTIONS WITH THIS MEDICATION</strong></p><p>Drugs that may interact with Bosentor include warfarin, simvastatin and other statins, glyburide, ketoconazole, cyclosporine A, tacrolimus, sirolimus and hormonal contraceptives.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Bosentor exactly as your doctor has instructed you. You should check with your doctor</p><p>or pharmacist if you are unsure.</p><p><strong>Usual dose:</strong></p><p>The usual dose is one tablet, swallowed twice daily (morning and evening), consistently with or</p><p>without food. For the first 4 weeks, you will take a 62.5 mg tablet twice daily, from then on, your doctor</p><p>will advise you to take a 125 mg tablet twice daily, depending on how you react to Bosentor.</p><p><strong>Overdose:</strong></p><p>If you take more tablets than you have been told to take, see a doctor or go to a hospital immediately</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>In case of drug overdose, contact a health care practitioner, hospital emergency department or</p><p>regional Poison Control Center immediately, even if there are no symptoms.</p></td></tr></tbody></table><p><strong>Missed Dose:</strong></p><p>If you forget to take Bosentor, take a dose as soon as you remember, then continue to take your tablets</p><p>at the usual time. Do not take a double dose to make up for forgotten tablets.</p><p><strong>Stopping treatment:</strong></p><p>Suddenly stopping your treatment with Bosentor may lead to a worsening of your symptoms. Do not</p><p>stop taking Bosentor unless your doctor tells you to. Your doctor may tell you to reduce the dose over</p><p>a few days before stopping completely.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Bosentor can have side effects even when used as directed.</p><p><strong>If you notice yellowing of the skin or eyes (jaundice) or other symptoms such as nausea, vomiting,</strong></p><p><strong>fever, abdominal pain or unusual tiredness, see your doctor immediately because this may be related to abnormal liver function.</strong></p><p>Headaches were the most common side effect in clinical studies. You may also notice one or more of the following side effects</p><p>&bull; flushed appearance, inflammation of the throat and nasal passages, swelling of the legs and ankles,</p><p>or other signs of fluid retention, low blood pressure, irregular heartbeat, heartburn, tiredness, itching, nausea. If these side effects become bothersome, contact your doctor.</p><p>Other less common side effects that you might notice:</p><p>&bull; vomiting, abdominal pain, diarrhea, skin rash.</p><p>If you notice any other side effects or signs of allergic reaction (e.g. swelling of the face or tongue, rash, pruritus) while you are taking Bosentor or if any of the side effects mentioned above worries you, please inform your doctor or pharmacist.</p><table border="1" cellspacing="0" cellpadding="0" style="width:360px"><thead><tr><td colspan="4" style="vertical-align:top">&nbsp;<p><strong>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Symptom / effect</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Talk with your doctor or pharmacist</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Stop taking drug and seek immediate emergency medical attention</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Only if severe</strong></p></td><td style="vertical-align:top"><p><strong>In all cases</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Common</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Itching</p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Other signs of fluid retention</p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Swelling of the legs and ankles</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tiredness</p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Swelling of the face, throat or tongue</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p>Asthma like symptoms (wheezing)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Yellowing of the skin and eyes (jaundice)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&uuml;</strong></p><p>Call your doctor immediately</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>This is not a complete list of side effects. For any unexpected effects while taking Bosentor, contact</p><p>your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach and sight of children. Do not store above 30&ordm;C. Do not use after the expiry date</p><p>stated on the label.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. What Bosentor contains</p><p>The active substance is: Bosentan monohydrate.</p><p>The other ingredients are Magnesium stearate, povidone, pregelatinized starch, sodium starch</p><p>glycolate the film-coating is composed of hydroxypropyl methylcellulose, iron oxide red, iron oxide yellow, titanium dioxide and triacetin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Bosentor 62.5 mg tablets are orange-white round, coated tablet debossed with “B” on one side and
“62.5” on the other side
Bosentor 125 mg tablets are orange-white ovaloid, coated tablet debossed with “B” on one side and
“125” on the other side
Each pack of Bosentor 62.5 mg & Bosentor 125 mg contains blisters of 60 (15’sx4) tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder:</p><p>Pharma Pharmaceutical Industry, Saudi Arabia</p><p>Second Industrial Zone, Riyadh, Saudi Arabia.</p><p>www.pharma.com.sa</p><p>Email: info@pharma.com.sa</p><p>Manufacturer:</p><p>Genvion Corporation for Pharmascience Inc. Canada</p><p>500 Camiel System street, Winnipeg, Mannitoba, R2J 4K2, Winnipeg, Canada.</p><p>To report any side effect(s):</p><p><strong>S</strong><strong>audi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC) </strong></p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>Other GCC states:</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:2.4pt;margin-top:3.35pt;width:252.95pt;
 height:20.5pt;text-indent:0;z-index:251658240;mso-width-relative:margin;
 mso-height-relative:margin'>
 <v:textbox style='mso-next-textbox:#_x0000_s1026'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Please contact the relevant competent authority.</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>f.Council of Arab Health Ministers</strong></p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:2.4pt;
 margin-top:6.35pt;width:259.7pt;height:134.7pt;z-index:251659264;
 mso-width-relative:margin;mso-height-relative:margin'>
 <v:textbox style='mso-next-textbox:#_x0000_s1027'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>This is a Medicament</strong></p><p>Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.</p><p> Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p> The doctor and the pharmacist are the experts in medicines, their benefits and risks.</p><p> Do not by yourself interrupt the period of treatment prescribed for you.</p><p> Do not repeat the same prescription without consulting your doctor.</p><p> Keep all medicaments out of reach of children.</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Council of Arab Health Ministers</p><p>Union of Arab Pharmacists</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">بوسينتور (بوسينتان) أقراص تُستخدم في علاج ارتفاع ضغط الدم الناتج عن توتر وضيق الشراين الرئوية ( ارتفاع ضغط الدم في الأوعية الدموية الواقعة في المنطقة بين القلب والرئتين) .</p><p dir="RTL">بوسينتور يقلل من ضغط الدم المرتفع بطريقة غير اعتيادية بإرخاء تلك الأوعية الدموية. ووتنتمي أقراص بوسينتور إلى مجموعة الأدوية المسماة مضادات مستقبلات الإندوثيلين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الفحوصات التي سوف يجريها الطبيب قبل إعطائك الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp; فحص وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp; فحص الأنيميا (انخفاض عدد كرات الدم الحمراء)</p><p dir="RTL">&middot;&nbsp;&nbsp; اختبار الحمل</p><p><strong>ما هي الظروف التي لا يجب عندها استخدام بوسينتور ؟</strong></p><p>&nbsp;</p><p dir="RTL">لا تستخدم بوسينتور في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تعاني من حساسية للبوسينتان أو لأي من مكوناته ( انظر المكونات غير الطبية).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كانت لديك مشاكل في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنتي حاملاً أو في نيتك الحمل (حبوب منع الحمل وحدها لا تكون لديها الفعالية المطلوبة في منع الحمل عند استعمال بوسينتور).</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنتي امرأة في سن الحمل ولا تستخدمي وسيلة منع حمل مناسبة.</p><p dir="RTL">&middot;&nbsp;&nbsp; إذا كنت تعالج بالسيكلوسبورين أ ، أو بالجلايبورايد.</p><p dir="RTL">أخبري طبيبك فورا إذا كنتي حاملا أو في نيتك أن تحملي في المستقبل القريب، حيث أن بوسينتور يمكن أن يضر الجنين، وعليه فإن أي سيدة حامل يجب أن تمتنع عن تناول بوسينتور كما يجب على من تستخدم بوسينتور ألا تحمل. وإذا كنتي سيدة في سن الحمل فإن طبيبك (طبيب النساء والولادة) سوف ينصحك بالنوع المناسب من وسائل منع الحمل في الوقت الذي تتناولين فيه بوسينتور . ولأن بوسينتور يمكن أن يجعل وسائل منع الحمل الهرمونية غير فعالة ( مثل وسائل منع الحمل عن طريق الفم أو الحقن أو اللصقات أو الزرع تحت البشرة) فإن تلك الوسائل يجب ألا تستخدم بمفردها، فإذا كنتي تستخدمين وسيلة هرمونية يجب أيضا أن تستخدمي وسيلة واقية مثل الواقي الأنثوي لك أو الواقي الذكري للزوج أو الأسفنجة المانعة للحمل) ويفضل عمل اختبارات حمل شهرية أثناء تناول المرأة عقار بوسينتور وهي في سن الحمل .</p><p dir="RTL">أخبري طبيبك فوراً إذا كنتي تقومين بإرضاع طفلك. وينصح بوقف الإرضاع من الثدي إذا كنت سوف تعالجين ب بوسينتور نظرا لعدم معرفة إذا كان العقار يظهر في حليب الأم أم لا .</p><p dir="RTL">إذا شعرت بالدوخة أثناء المعالجة ب بوسينتور تجنب قيادة السيارات أو تشغيل أي ماكينات أو آلات .</p><p>لا ينصح بإعطاء بوسينتور للأطفال</p><p><strong>تحذيرات واحتياطات يجب إتخاذها </strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">تحذيرات واحتياطات</p><p dir="RTL">قبل استخدام بوسينتور، استشر طبيبك إذا كنت:</p><p dir="RTL">&middot;&nbsp;&nbsp; تعاني من مشاكل في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp; حامل أو في نيتك الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp; سيدة في سن الإنجاب ولا تستخدمين وسيلة مناسبة لمنع الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp; مرضعة.</p>تعاني من حساسية للبوسينتان أو أي من مكونات أقراص&nbsp; بوسينتور.</td></tr></tbody></table><p dir="RTL">قبل بدء العلاج بعقار بوسينتور أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت في السابق أي دواء آخر حتى تلك الأدوية التي تشتريها بنفسك. ومن الأهمية بمكان إخبار الطبيب إذا كنت تستخدم أدوية مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp; وسائل منع الحمل الهرمونية ( حيث أنها تصبح غير فعالة إذا استخدمت بمفردها مع استخدام بوسينتور).</p><p dir="RTL">&middot;&nbsp;&nbsp; جلايبورايد (للسكري).</p><p dir="RTL">&middot;&nbsp;&nbsp; سيكلوسبورين أ (وهو دواء يستخدم بعد عمليات زرع الأعضاء وأيضاً في علاج الصدفية) أو أي أدوية تثبط رفض الجسم للعضو المزروع.</p><p dir="RTL">&middot;&nbsp;&nbsp; &nbsp;فلوكونازول (وهو دواء يستخدم في علاج أشكال العدوى الفطرية).</p><p dir="RTL">&middot;&nbsp;&nbsp; ريفامبيسين ( دواء يستخدم في علاج السل الرئوي).</p><p dir="RTL"><strong>فحوصات أثناء المعالجة</strong> :</p><p dir="RTL">تظهر نتائج التحليل لدى بعض المرضى الذين يستخدمون بوسينتور قيم غير عادية لوظائف الكبد (زيادة في إنزيمات الكبد) وبعض المرضي يصابون بالأنيميا (انخفاض في كرات الدم الحمرات).&nbsp;</p><p dir="RTL">ونظراً لأن هذه المشاكل لا تظهر لها أعراض يشعر بها أو يلاحظها المريض فإن الطبيب يطلب منه إجراء عدة فحوصات لتقييم أي تغيير يحدث على وظائف الكبد وعلى مستوى الهيموجلوبين.</p><p dir="RTL"><strong>وظائف الكبد :</strong></p><p dir="RTL">يتم إجراء هذا الفحص :</p><p dir="RTL">&middot;&nbsp;&nbsp; مرة واحدة أو أكثر (حسب الحاجة) كل شهر.</p><p dir="RTL">فإذا أظهرت الفحوصات زيادة في وظائف الكبد عن الحد الطبيعي يقوم الطبيب بتخفيض الجرعة أو إيقاف المعالجة بعقار بوسينتور. فإذا عادت وظائف الكبد إلى وضعها الطبيعي، عندئذ يمكن للطبيب معاودة العلاج مرة أخرى بعقار بوسينتور.</p><p dir="RTL"><strong>الأنيميا : </strong></p><p dir="RTL">يتم إجراء هذا الفحص :</p><p dir="RTL">&middot;&nbsp;&nbsp; بعد مضي شهر ثم بعد مضي 3 شهور وذلك من بداية العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp; مرة كل 3 شهور بعد ذلك.</p><p dir="RTL">إذا أصيب المريض بالأنيميا يقوم الطبيب بإجراء المزيد من الفحوصات للتأكد من السبب.</p><p dir="RTL">تُعد القيم الطبيعية لفحوص الدم لكل من إنزيمات الكبد والأنيميا جزءاً هاماً في علاجك . لذلك نقترح أن تسجل في مذكرة خاصة بك تاريخ آخر فحص للدم قمت بإجرائه والتاريخ الذي يجب أن يتم فيه إجراء الفحص القادم (اسأل طبيبك عن ذلك التاريخ) حتى لا يفوتك موعد الفحص.</p><p dir="RTL"><strong>فحص الحمل للسيدات في سن الإنجاب</strong>:</p><p dir="RTL">نظرا لوجود احتمال انعدام فاعلية وسائل منع الحمل الهرمونية مع استخدام بوسينتور ، واحتمال تدهور حالة مرضى ارتفاع ضغط الدم بالأوعية الدموية بين القلب والرئتين فإنه يجب إجراء اختبار الحمل قبل العلاج بعقار بوسينتور ثم شهرياً أثناء العلاج.</p><p><strong>التفاعل مع الأدوية الأخرى </strong></p><p dir="RTL">من بين الأدوية التي تتفاعل مع بوسينتور ما يلي: وارفارين، سيمفاستاتين والستاتينات الأخرى، جلايبورايد، كيتوكينازول، سايكلوسبورين أ، تاكروليموس، سيروليموس، موانع الحمل الهرمونية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول الدواء تماما كما أمر به الطبيب، استشر الطبيب أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الجرعة المعتادة</strong> :</p><p dir="RTL">الجرعة المعتادة هي قرص واحد يبلع كاملا مرتان في اليوم (صباحاً ومساءاً) سواء مع الطعام أو بدونه. في أول 4 أسابيع يتم تناول جرعة قرص 62.5 مج&nbsp; مرتين في اليوم وبعدها سوف ينصح الطبيب بتناول جرعة 125 مج مرتين في اليوم حسب استجابة المريض للعلاج .</p><p dir="RTL"><strong>الجرعة المفرطة</strong> :</p><p dir="RTL">إذ أخذت عدد من الأقراص أكثر من الجرعة التي من المفروض أن تأخذها راجع طبيبك أو اذهب إلى المستشفى فوراً.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">في حالة تناول جرعة مفرطة من الدواء اتصل فوراً بمسئول صحي أو بقسم الطوارئ في أي مستشفى أو بقسم مكافحة السموم وذلك حتى في حالة عدم ظهور أي أعراض.</p></td></tr></tbody></table><p dir="RTL">&nbsp;<strong>إذا فاتتك جرعة</strong>:</p><p dir="RTL">إذا نسيت جرعتك من بوسينتور تناول جرعة حالما تتذكر. وبعد ذلك تناول الجرعة التالية في الموعد المعتاد. ولا تأخذ جرعة مضاعفة لتعويض الجرعة التي نسيت تناولها.</p><p dir="RTL"><strong>إيقاف العلاج</strong> :</p><p dir="RTL">الإيقاف المفاجئ للعلاج بالدواء يمكن أن يؤدي إلى تدهور حالة المريض. ولا تتوقف عن تناول بوسينتور من تلقاء نفسك بدون تعليمات الطبيب. ويمكن لطبيبك أن يوصي بتخفيض الجرعة على عدة أيام قبل التوقف التام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، يمكن لعقار بوسينتور أن يكون له أعراض جانبية حتى مع استخدامه بالطريقة التي يوصي بها الطبيب.</p><p dir="RTL"><strong>إذا لاحظت وجود اصفرار في لون الجلد ( الصفرة ) أو أي أعراض أخرى مثل الغثيان أو القيء أو الحمى أو المغص أو التعب غير المعتاد، راجع طبيبك فوراً، حيث أن ذلك يمكن أن يكون ناتجا عن اضطراب في وظائف الكبد</strong>.</p><p dir="RTL">والصداع هو أكثر الآثار الجانبية الشائعة التي تم ملاحظتها في الدراسات السريرية.</p><p dir="RTL">&nbsp;ويمكن أيضا ملاحظة بعض من الآثار الجانبية التالية:</p><p dir="RTL">&middot; احمرار الوجه ، التهاب الحلق والمجاري التنفسية، تورم الساقين ومفصل القدم ، أو علامات أخرى مثل احتباس السوائل، انخفاض ضغط الدم، عدم انتظام ضربات القلب، حموضة في المعدة، إرهاق، حكة، غثيان.&nbsp; وإذ ظهرأي من هذه الأعراض بصورة تضايقك راجع طبيبك.</p><p dir="RTL">أعراض أخرى أقل شيوعا:</p><p dir="RTL">&middot; القيء، المغص، الإسهال، الطفح الجلدي.</p><p dir="RTL">إذا لاحظت أعراضاً أخرى أو مظاهر للحساسية (مثل تورم الوجه أو اللسان، الطفح الجلدي، الحكة) أثناء العلاج بعقار بوسينتور أو ضايقتك الأعراض الجانبية المذكورة أعلاه يرجى مراجعة طبيبك أو الصيدلي.</p><p><img src="data:image/jpeg;base64,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" alt="" width="500" height="628" vspace="0" hspace="0" border="0" style="width:500px;height:628px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول نظر وأيدي الأطفال. ويخزن في درجة حرارة أقل من 30 مئوية. ولا يستعمل بعد تاريخ انتهاء الصلاحية المطبوع على العلبة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي : بوسينتان مونوهيدريت</p><p dir="RTL">المواد الأخرى التي تدخل في تركيب بوسينتور هي: سترات الماغنيسيوم ، بوفيدون، نشاء معالج مسبقا بالجيلاتين، جلايكوليت نشاء الصوديوم، والغشاء المغلف للقرص مكون من: هيدروكسيبروبيل ميثيلسيليلوز، أكسيد الحديد الأحمر، أكسيد الحديد الأصفر، ثاني أكسيد التيتانيوم، تراياسيتين.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كيف يبدو شكل بوسينتور وما هي محتويات العبوة ؟</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; أقراص بوسينتور 62.5 مج هي أقراص مستديرة ذات لونين أبيض/برتقالي مغلفة عليها علامة B &nbsp;من جانب وعلامة 62.5 من الجانب الآخر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; أقراص بوسينتور 125 مج هي أقراص بيضاوية ذات لونين أبيض/برتقالي مغلفة عليها علامة B &nbsp;من جانب وعلامة 125 من الجانب الآخر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp; علبة كل من بوسينتور 62.5 مج و بوسينتور 125 مج تحتوي على شرائط بها 60 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة فرماء للصناعات الدوائية</p><p dir="RTL">الرياض، المدينة الصناعية الثانية، مخرج 16</p><p dir="RTL">رقم الهاتف: +966114603099&nbsp; رقم الفاكس: +966114603163</p><p dir="RTL">www.pharma.com.sa</p><p dir="RTL">info@pharma.com.sa</p><p><strong>الشركة الصانعة:</strong></p><p>جينفيون كوربوريشن لصالح فارما ساينس انك. كندا</p><p>500 شارع كاميل سستم، وينيبق، مانيتوبا،&nbsp; كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bosentor 125 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 125 mg bosentan (as monohydrate).
Excipients with known effect: Not Applicable

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablets): Orange-white ovaloid, coated tablet debossed with “B” on one side and “125” on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary (idiopathic and heritable) pulmonary arterial hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger&#39;s physiology</p><p>Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II (see section 5.1).</p><p>Bosentan is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Method of administration</u></p><p>Tablets are to be taken orally morning and evening, with or without food. The film-coated tablets are to be swallowed with water.</p><p><u>Posology</u></p><p><u>Pulmonary arterial hypertension</u></p><p>Treatment should only be initiated and monitored by a physician experienced in the treatment of pulmonary arterial hypertension.</p><p><em><u>Adults</u></em></p><p>In adult patients, Bosentor treatment should be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily. The same recommendations apply to re-introduction of Bosentor after treatment interruption (see section 4.4).</p><p><em><u>Paediatric population</u></em></p><p>In children, the optimal maintenance dose has not been defined in well-controlled studies. However, paediatric pharmacokinetic data have shown that bosentan plasma concentrations in children were on average lower than in adult patients and were not increased by increasing the dose of Bosentor above 2 mg/kg body weight twice daily (see section 5.2). Based on these pharmacokinetic results, higher doses are unlikely to be more effective, and greater adverse reaction rates cannot formally be excluded in young children if the dose is increased. When used in children 2 years and older, the recommended starting and maintenance dose is therefore 2 mg/kg morning and evening. No clinical study has been conducted to compare the efficacy/safety ratio of 2 mg/kg to 4 mg/kg body weight twice daily in children.</p><p>There is only limited clinical experience in paediatric patients under 2 years of age.</p><p><em>Management in case of clinical deterioration of PAH</em></p><p>In the case of clinical deterioration (e.g., decrease in 6-minute walk test distance by at least 10% compared with pre-treatment measurement) despite Bosentor treatment for at least 8 weeks (target dose for at least 4 weeks), alternative therapies should be considered. However, some patients who show no response after 8 weeks of treatment with Bosentor may respond favourably after an additional 4 to 8 weeks of treatment.</p><p>In the case of late clinical deterioration despite treatment with Bosentor (i.e., after several months of treatment), the treatment should be re-assessed. Some patients not responding well to 125 mg twice daily of Bosentor may slightly improve their exercise capacity when the dose is increased to 250 mg twice daily. A careful benefit/risk assessment should be made, taking into consideration that the liver toxicity is dose dependent (see sections 4.4 and 5.1).</p><p><em>Discontinuation of treatment</em></p><p>There is limited experience with abrupt discontinuation of Bosentor in patients with pulmonary arterial hypertension. No evidence for acute rebound has been observed. However, to avoid the possible occurrence of harmful clinical deterioration due to potential rebound effect, gradual dose reduction (halving the dose for 3 to 7 days) should be considered. Intensified monitoring is recommended during the discontinuation period.</p><p>If the decision to withdraw Bosentor is taken, it should be done gradually while an alternative therapy is introduced.</p><p><u>Systemic sclerosis with ongoing digital ulcer disease</u></p><p>Treatment should only be initiated and monitored by a physician experienced in the treatment of systemic sclerosis.</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p>Bosentor treatment should be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily. The same recommendations apply to re-introduction of Bosentor after treatment interruption (see section 4.4).</p><p>Controlled clinical study experience in this indication is limited to 6 months (see section 5.1).</p><p>The patient&#39;s response to treatment and need for continued therapy should be re-evaluated on a regular basis. A careful benefit/risk assessment should be made, taking into consideration the liver toxicity of bosentan (see sections 4.4 and 4.8).</p><p><em><u>Paediatric population</u></em></p><p>There are no data on the safety and efficacy in patients under the age of 18 years. Pharmacokinetic data are not available for Bosentor in young children with this disease.</p><p><u>Special populations</u></p><p><em>Patients with hepatic impairment</em></p><p>Bosentor is contraindicated in patients with moderate to severe liver dysfunction (see sections 4.3, 4.4 and 5.2). No dose adjustment is needed in patients with mild hepatic impairment (i.e., Child-Pugh class A) (see section 5.2).</p><p><em>Patients with renal impairment</em></p><p>No dose adjustment is required in patients with renal impairment. No dose adjustment is required in patients undergoing dialysis (see section 5.2).</p><p><em>Elderly population</em></p><p>No dose adjustment is required in patients over the age of 65 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
• Moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 5.2) 
• Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT), greater than 3 times the upper limit of normal (see section 4.4) 
• Concomitant use of cyclosporine A (see section 4.5) 
• Pregnancy (see sections 4.4 and 4.6) 
• Women of child-bearing potential who are not using reliable methods of contraception (see sections 4.4, 4.5 and 4.6) 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:850px"><tbody><tr><td><p><strong>WARNING: </strong>RISKS OF HEPATOTOXICITY and TERATOGENICITY Hepatotoxicity In clinical studies, Bosentan caused at least 3-fold upper limit of normal (ULN) elevation of liver aminotransferases (ALT and AST) in about 11% of patients, accompanied by elevated bilirubin in a small number of cases. Because these changes are a marker for potential serious hepatotoxicity, serum aminotransferases levels must be measured prior to initiation of treatment and then monthly.</p><p>In the post marketing period, in the setting of close monitoring, rare cases of unexplained hepatic cirrhosis were reported after prolonged (&gt; 12 months) therapy with Bosentan in patients with multiple comorbidities and drug therapies. There have also been reports of liver failure. The contribution of Bosentan in these cases could not be excluded.</p><p>In at least one case, the initial presentation (after &gt; 20 months of treatment) included pronounced elevations in aminotransferases and bilirubin levels accompanied by nonspecific symptoms, all of which resolved slowly over time after discontinuation of Bosentan. This case reinforces the importance of strict adherence to the monthly monitoring schedule for the duration of treatment and the treatment algorithm, which includes stopping Bosentan with a rise of aminotransferases accompanied by signs or symptoms of liver dysfunction. Elevations in aminotransferases require close attention. Bosentan should generally be avoided in patients with elevated aminotransferases (&gt; 3 &times;ULN) at baseline because monitoring for hepatotoxicity may be more difficult. If liver aminotransferases elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin &ge; 2 &times; ULN, treatment with Bosentan should be stopped. There is no experience with the reintroduction of Bosentan in these circumstances.</p><p><strong>Teratogenicity</strong></p><p>Bosentan is likely to cause major birth defects if used by pregnant females based on animal data. Therefore, pregnancy must be excluded before the start of treatment with Bosentan. Throughout treatment and for one month after stopping Bosentan, females of childbearing potential must use two reliable methods of contraception. Hormonal contraceptives, including oral, injectable, transdermal, and implantable contraceptives should not be used as the sole means of contraception because these may not be effective in patients receiving Bosentan.</p></td></tr></tbody></table><p>The efficacy of Bosentor has not been established in patients with severe pulmonary arterial hypertension. Transfer to a therapy that is recommended at the severe stage of the disease (e.g., epoprostenol) should be considered if the clinical condition deteriorates (see section 4.2).</p><p>The benefit/risk balance of bosentan has not been established in patients with WHO class I functional status of pulmonary arterial hypertension.</p><p>Bosentor should only be initiated if the systemic systolic blood pressure is higher than 85 mmHg.</p><p>Bosentor has not been shown to have a beneficial effect on the healing of existing digital ulcers.</p><p><u>Liver function</u></p><p>Elevations in liver aminotransferases, i.e., aspartate and alanine aminotransferases (AST and/or ALT), associated with bosentan are dose dependent. Liver enzyme changes typically occur within the first 26 weeks of treatment but may also occur late in treatment (see section 4.8). These increases may be partly due to competitive inhibition of the elimination of bile salts from hepatocytes but other mechanisms, which have not been clearly established, are probably also involved in the occurrence of liver dysfunction. The accumulation of bosentan in hepatocytes leading to cytolysis with potentially severe damage of the liver, or an immunological mechanism, are not excluded. Liver dysfunction risk may also be increased when medicinal products that are inhibitors of the bile salt export pump, e.g., rifampicin, glibenclamide and cyclosporine A (see sections 4.3 and 4.5), are co-administered with bosentan, but limited data are available.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Liver aminotransferase levels must be measured prior to initiation of treatment and subsequently at monthly intervals for the duration of treatment with Bosentor</strong>. <strong>In addition, liver aminotransferase levels must be measured 2 weeks after any dose increase.</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Recommendations in case of ALT/AST elevations</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ALT/AST levels</strong></p></td><td style="vertical-align:top"><p><strong>Treatment and monitoring recommendations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 3 and &le; 5 &times; ULN</p></td><td style="vertical-align:top"><p>The result should be confirmed by a second liver test; if confirmed, a decision should be made on an individual basis to continue Bosentor, possibly at a reduced dose, or to stop Bosentor administration (see section 4.2). Monitoring of aminotransferase levels should be continued at least every 2 weeks. If the aminotransferase levels return to pre-treatment values continuing or re-introducing Bosentor according to the conditions described below should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 5 and &le; 8 &times; ULN</p></td><td style="vertical-align:top"><p>The result should be confirmed by a second liver test; if confirmed, treatment should be stopped and aminotransferase levels monitored at least every 2 weeks. If the aminotransferase levels return to pre-treatment values re-introducing Bosentor according to the conditions described below should be considered.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 8 &times; ULN</p></td><td style="vertical-align:top"><p>Treatment must be stopped and re-introduction of Bosentor is not to be considered.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>In the case of associated clinical symptoms of liver injury</strong>, i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever),<strong> treatment must be stopped and re-introduction of Bosentor is not to be considered.</strong></p><p><em><u>Re-introduction of treatment</u></em></p><p>Re-introduction of treatment with Bosentor should only be considered if the potential benefits of treatment with Bosentor outweigh the potential risks and when liver aminotransferase levels are within pre-treatment values. The advice of a hepatologist is recommended. Re-introduction must follow the guidelines detailed in section 4.2. <strong>Aminotransferase levels must then be checked within 3 days after re-introduction, then again after a further 2 weeks, and thereafter according to the recommendations above.</strong></p></td></tr></tbody></table><p>ULN = Upper Limit of Normal</p><p><u>Haemoglobin concentration</u></p><p>Treatment with bosentan has been associated with dose-related decreases in haemoglobin concentration (see section 4.8). In placebo-controlled studies, bosentan-related decreases in haemoglobin concentration were not progressive, and stabilised after the first 4&ndash;12 weeks of treatment. It is recommended that haemoglobin concentrations be checked prior to initiation of treatment, every month during the first 4 months, and quarterly thereafter. If a clinically relevant decrease in haemoglobin concentration occurs, further evaluation and investigation should be undertaken to determine the cause and need for specific treatment. In the post-marketing period, cases of anaemia requiring red blood cell transfusion have been reported (see section 4.8).</p><p><u>Women of child-bearing potential</u></p><p>As Bosentor may render hormonal contraceptives ineffective, and taking into account the risk that pulmonary hypertension deteriorates with pregnancy as well as the teratogenic effects observed in animals:</p><p>&bull; Bosentor treatment must not be initiated in women of child-bearing potential unless they practise reliable contraception and the result of the pre-treatment pregnancy test is negative</p><p>&bull; Hormonal contraceptives cannot be the sole method of contraception during treatment with Bosentor</p><p>&bull; Monthly pregnancy tests are recommended during treatment to allow early detection of pregnancy</p><p>For further information see sections 4.5 and 4.6.</p><p><u>Pulmonary veno-occlusive disease</u></p><p>Cases of pulmonary oedema have been reported with vasodilators (mainly prostacyclins) when used in patients with pulmonary veno-occlusive disease. Consequently, should signs of pulmonary oedema occur when Bosentor is administered in patients with PAH, the possibility of associated veno-occlusive disease should be considered. In the post-marketing period there have been rare reports of pulmonary oedema in patients treated with Bosentor who had a suspected diagnosis of pulmonary veno-occlusive disease.</p><p><u>Pulmonary arterial hypertension patients with concomitant left ventricular failure</u></p><p>No specific study has been performed in patients with pulmonary hypertension and concomitant left ventricular dysfunction. However, 1,611 patients (804 bosentan- and 807 placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean duration of 1.5 years in a placebo-controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]). In this study there was an increased incidence of hospitalisation due to CHF during the first 4&ndash;8 weeks of treatment with bosentan, which could have been the result of fluid retention. In this study, fluid retention was manifested by early weight gain, decreased haemoglobin concentration and increased incidence of leg oedema. At the end of this study, there was no difference in overall hospitalisations for heart failure nor in mortality between bosentan- and placebo-treated patients. Consequently, it is recommended that patients be monitored for signs of fluid retention (e.g., weight gain), especially if they concomitantly suffer from severe systolic dysfunction. Should this occur, starting treatment with diuretics is recommended, or the dose of existing diuretics should be increased. Treatment with diuretics should be considered in patients with evidence of fluid retention before the start of treatment with Bosentor.</p><p>&nbsp;</p><p><u>Pulmonary arterial hypertension associated with HIV infection</u></p><p>There is limited clinical study experience with the use of Bosentor in patients with PAH associated with HIV infection, treated with antiretroviral medicinal products (see section 5.1). An interaction study between bosentan and lopinavir+ritonavir in healthy subjects showed increased plasma concentrations of bosentan, with the maximum level during the first 4 days of treatment (see section 4.5). When treatment with Bosentor is initiated in patients who require ritonavir-boosted protease inhibitors, the patient&#39;s tolerability of Bosentor should be closely monitored with special attention, at the beginning of the initiation phase, to the risk of hypotension and to liver function tests. An increased long-term risk of hepatic toxicity and haematological adverse events cannot be excluded when bosentan is used in combination with antiretroviral medicinal products. Due to the potential for interactions related to the inducing effect of bosentan on CYP450 (see section 4.5), which could affect the efficacy of antiretroviral therapy, these patients should also be monitored carefully regarding their HIV infection.</p><p><u>Pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)</u></p><p>Safety and tolerability of bosentan was investigated in an exploratory, uncontrolled 12-week study in 11 patients with pulmonary hypertension secondary to severe COPD (stage III of GOLD classification). An increase in minute ventilation and a decrease in oxygen saturation were observed, and the most frequent adverse event was dyspnoea, which resolved with discontinuation of bosentan.</p><p><u>Concomitant use with other medicinal products</u></p><p>Concomitant use of Bosentor and cyclosporine A is contraindicated (see sections 4.3 and 4.5).</p><p>Concomitant use of Bosentor with glibenclamide, fluconazole and rifampicin is not recommended. For further details please refer to section 4.5.</p><p>Concomitant administration of both a CYP3A4 inhibitor and a CYP2C9 inhibitor with Bosentor should be avoided (see section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bosentan is an inducer of the cytochrome P450 (CYP) isoenzymes CYP2C9 and CYP3A4. <em>In vitro</em> data also suggest an induction of CYP2C19. Consequently, plasma concentrations of substances metabolised by these isoenzymes will be decreased when Bosentor is co-administered. The possibility of altered efficacy of medicinal products metabolised by these isoenzymes should be considered. The dosage of these products may need to be adjusted after initiation, dose change or discontinuation of concomitant Bosentor treatment.</p><p>Bosentan is metabolised by CYP2C9 and CYP3A4. Inhibition of these isoenzymes may increase the plasma concentration of bosentan (see ketoconazole). The influence of CYP2C9 inhibitors on bosentan concentration has not been studied. The combination should be used with caution.</p><p><em>&nbsp;</em></p><p><em>Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: </em>Concomitant administration with fluconazole, which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead to large increases in plasma concentrations of bosentan. The combination is not recommended. For the same reason, concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with Bosentor is not recommended.</p><p><em>&nbsp;</em></p><p><em>Cyclosporine A:</em> co-administration of Bosentor and cyclosporine A (a calcineurin inhibitor) is contraindicated (see section 4.3). When co-administered, initial trough concentrations of bosentan were approximately 30-fold higher than those measured after bosentan alone. At steady state, bosentan plasma concentrations were 3- to 4-fold higher than with bosentan alone. The mechanism of this interaction is most likely inhibition of transport protein-mediated uptake of bosentan into hepatocytes by cyclosporine. The blood concentrations of cyclosporine A (a CYP3A4 substrate) decreased by approximately 50%. This is most likely due to induction of CYP3A4 by bosentan.</p><p><em>&nbsp;</em></p><p><em>Tacrolimus, sirolimus:</em> co-administration of tacrolimus or sirolimus and Bosentor has not been studied in man but co-administration of tacrolimus or sirolimus and Bosentor may result in increased plasma concentrations of bosentan in analogy to co-administration with cyclosporine A. Concomitant Bosentor may reduce the plasma concentrations of tacrolimus and sirolimus. Therefore, concomitant use of Bosentor and tacrolimus or sirolimus is not advisable. Patients in need of the combination should be closely monitored for adverse events related to Bosentor and for tacrolimus and sirolimus blood concentrations.</p><p><em>&nbsp;</em></p><p><em>Glibenclamide:</em> co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of glibenclamide (a CYP3A4 substrate) by 40%, with potential significant decrease of the hypoglycaemic effect. The plasma concentrations of bosentan were also decreased by 29%. In addition, an increased incidence of elevated aminotransferases was observed in patients receiving concomitant therapy. Both glibenclamide and bosentan inhibit the bile salt export pump, which could explain the elevated aminotransferases. This combination should not be used. No drug-drug interaction data are available with the other sulfonylureas.</p><p><em>&nbsp;</em></p><p><em>Rifampicin:</em> co-administration in 9 healthy subjects for 7 days of bosentan 125 mg twice daily with rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma concentrations of bosentan by 58%, and this decrease could achieve almost 90% in an individual case. As a result, a significantly reduced effect of bosentan is expected when it is co-administered with rifampicin. Concomitant use of rifampicin and Bosentor is not recommended. Data on other CYP3A4 inducers, e.g., carbamazepine, phenobarbital, phenytoin and St. John&#39;s wort are lacking, but their concomitant administration is expected to lead to reduced systemic exposure to bosentan. A clinically significant reduction of efficacy cannot be excluded.</p><p><em>&nbsp;</em></p><p><em>Lopinavir+ritonavir (and other ritonavir-boosted protease inhibitors): </em>co-administration of bosentan 125 mg twice daily and lopinavir+ritonavir 400+100 mg twice daily for 9.5 days in healthy volunteers resulted in initial trough plasma concentrations of bosentan that were approximately 48-fold higher than those measured after bosentan administered alone. On day 9, plasma concentrations of bosentan were approximately 5-fold higher than with bosentan administered alone. Inhibition by ritonavir of transport protein-mediated uptake into hepatocytes and of CYP3A4, thereby reducing the clearance of bosentan, most likely causes this interaction. When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient&#39;s tolerability of Bosentor should be monitored.</p><p>&nbsp;</p><p>After co-administration of bosentan for 9.5 days, the plasma exposures to lopinavir and ritonavir decreased to a clinically non significant extent (by approximately 14% and 17%, respectively). However, full induction by bosentan might not have been reached and a further decrease of protease inhibitors cannot be excluded. Appropriate monitoring of the HIV therapy is recommended. Similar effects would be expected with other ritonavir-boosted protease inhibitors (see section 4.4).</p><p><em>&nbsp;</em></p><p><em>Other antiretroviral agents:</em> no specific recommendation can be made with regard to other available antiretroviral agents due to the lack of data. Due to the marked hepatotoxicity of nevirapine, which could add to bosentan liver toxicity, this combination is not recommended.</p><p><em>&nbsp;</em></p><p><em>Hormonal contraceptives: </em>co-administration of bosentan 125 mg twice daily for 7 days with a single dose of oral contraceptive containing norethisterone 1 mg + ethinyl estradiol 35 mcg decreased the AUC of norethisterone and ethinyl estradiol by 14% and 31%, respectively. However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects. Therefore, hormone-based contraceptives alone, regardless of the route of administration (i.e., oral, injectable, transdermal or implantable forms), are not considered as reliable methods of contraception (see sections 4.4 and 4.6).</p><p><em>&nbsp;</em></p><p><em>Warfarin:</em> co-administration of bosentan 500 mg twice daily for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29% and 38%, respectively. Clinical experience with concomitant administration of bosentan with warfarin in patients with pulmonary arterial hypertension did not result in clinically relevant changes in International Normalized Ratio (INR) or warfarin dose (baseline versus end of the clinical studies). In addition, the frequency of changes in warfarin dose during the studies due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients. No dose adjustment is needed for warfarin and similar oral anticoagulant agents when bosentan is initiated, but intensified monitoring of INR is recommended, especially during bosentan initiation and the up-titration period.</p><p><em>&nbsp;</em></p><p><em>Simvastatin:</em> co-administration of bosentan 125 mg twice daily for 5 days decreased the plasma concentrations of simvastatin (a CYP3A4 substrate) and its active &beta;-hydroxy acid metabolite by 34% and 46%, respectively. The plasma concentrations of bosentan were not affected by concomitant simvastatin. Monitoring of cholesterol levels and subsequent dosage adjustment should be considered.</p><p><em>&nbsp;</em></p><p><em>Ketoconazole:</em> co-administration for 6 days of bosentan 62.5 mg twice daily with ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2-fold. No dose adjustment of Bosentor &nbsp;is considered necessary. Although not demonstrated through <em>in vivo</em> studies, similar increases in bosentan plasma concentrations are expected with the other potent CYP3A4 inhibitors (such as itraconazole or ritonavir). However, when combined with a CYP3A4 inhibitor, patients who are poor metabolisers of CYP2C9 are at risk of increases in bosentan plasma concentrations that may be of higher magnitude, thus leading to potential harmful adverse events.</p><p><em>&nbsp;</em></p><p><em>Epoprostenol:</em> limited data obtained from a study (AC-052-356 [BREATHE-3]) in which 10 paediatric patients received the combination of bosentan and epoprostenol indicate that after both single- and multiple-dose administration, the C<sub>max</sub> and AUC values of bosentan were similar in patients with or without continuous infusion of epoprostenol (see section 5.1).</p><p><em>&nbsp;</em></p><p><em>Sildenafil:</em> co-administration of bosentan 125 mg twice daily (steady state) with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63% decrease in the sildenafil AUC and a 50% increase in the bosentan AUC. Caution is recommended in the case of co-administration.</p><p><em>&nbsp;</em></p><p><em>Digoxin:</em> co-administration for 7 days of bosentan 500 mg twice daily with digoxin decreased the AUC, C<sub>max </sub>and C<sub>min </sub>of digoxin by 12%, 9% and 23%, respectively. The mechanism for this interaction may be induction of P-glycoprotein. This interaction is unlikely to be of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><strong> (Category X )</strong></p><p>Studies in animals have shown reproductive toxicity (teratogenicity, embryotoxicity, see &nbsp;&nbsp;&nbsp;section 5.3). There are no reliable data on the use of Bosentor in pregnant women. The potential risk for humans is still unknown. Bosentor is contraindicated in pregnancy (see section 4.3).</p><p><strong>Use in women of child-bearing potential</strong></p><p>Before the initiation of Bosentor treatment in women of child-bearing potential, the absence of pregnancy should be checked, appropriate advice on reliable methods of contraception provided, and reliable contraception initiated. Patients and prescribers must be aware that due to potential pharmacokinetic interactions, Bosentor may render hormonal contraceptives ineffective (see section 4.5). Therefore, women of child-bearing potential must not use hormonal contraceptives (including oral, injectable, transdermal or implantable forms) as the sole method of contraception but must use an additional or an alternative reliable method of contraception. If there is any doubt about what contraceptive advice should be given to the individual patient, consultation with a gynaecologist is recommended. Because of possible hormonal contraception failure during Bosentor treatment, and also bearing in mind the risk that pulmonary hypertension severely deteriorates with pregnancy, monthly pregnancy tests during treatment with Bosentor are recommended to allow early detection of pregnancy.</p><p><u>Breast-feeding</u></p><p>It is not known whether bosentan is excreted into human breast milk. Breast-feeding is not recommended during treatment with Bosentor.</p><p><u>Fertility</u></p><p>Fertility studies in rats showed no effects on sperm parameters or fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific studies have been conducted to assess the direct effect of Bosentor on the ability to drive and use machines. However, Bosentor may induce hypotension, with symptoms of dizziness or syncope that could affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 20 placebo-controlled studies, conducted in a variety of therapeutic indications, a total of 2,486 patients were treated with bosentan at daily doses ranging from 100 mg to 2000 mg and 1,838 patients were treated with placebo. The mean treatment duration was 45 weeks. Adverse reactions were defined as events occurring in at least 1% of patients on bosentan and at a frequency at least 0.5% more than on placebo. The most frequent adverse reactions are headache (11.5%), oedema/fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia/ haemoglobin decrease (9.9%).</p><p>Treatment with bosentan has been associated with dose-dependent elevations in liver aminotransferases and decreases in haemoglobin concentration (see section 4.4, Special warnings and precautions for use).</p><p>Adverse reactions observed in 20 placebo-controlled studies and post-marketing experience with bosentan are ranked according to frequency using the following convention: very common (&ge; 1/10); common (&ge;1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. No clinically relevant differences in adverse reactions were observed between the overall dataset and the approved indications.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia, haemoglobin decrease, (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaemia or haemoglobin decreases requiring red blood cell transfusion<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropenia, leukopenia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions (including dermatitis, pruritus and rash)<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylaxis and/or angioedema<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache<sup>3</sup>,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Syncope<sup>1, 4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Palpitations<sup>1, 4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension<sup>1, 4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease</p><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abnormal liver function test , (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Aminotransferase elevations associated with hepatitis and/or jaundice<sup>1</sup> (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Liver cirrhosis, liver failure<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erythema</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Oedema, fluid retention<sup>5</sup></p></td></tr></tbody></table><p><em><sup>&nbsp;</sup></em></p><p><em><sup>1</sup></em><em> Data derived from post-marketing experience, frequencies based on statistical modelling of placebo-controlled clinical trial data. </em></p><p><em><sup>2</sup></em><em> Hypersensitivity reactions were reported in 9.9% of patients on bosentan and 9.1% of patients on placebo. </em></p><p><em><sup>3 </sup></em><em>Headache was reported in 11.5% of patients on bosentan and 9.8% of patients on placebo. </em></p><p><em><sup>4</sup></em><em> These types of reactions can also be related to the underlying disease. </em></p><p><em><sup>5 </sup></em><em>Oedema or fluid retention was reported in 13.2% of patients on bosentan and 10.9% of patients on placebo. </em></p><p>&nbsp;</p><p>In the post-marketing period rare cases of unexplained hepatic cirrhosis were reported after prolonged therapy with Bosentor in patients with multiple co-morbidities and therapies with medicinal products. There have also been rare reports of liver failure. These cases reinforce the importance of strict adherence to the monthly schedule for monitoring of liver function for the duration of treatment with Bosentor (see section 4.4).</p><p><u>Paediatric population</u></p><p><u>Uncontrolled studies in paediatric patients with PAH (AC-052-356 [BREATHE-3]; AC-052-365 [FUTURE 1])</u></p><p>The safety profile in this population (BREATHE-3: n = 19, bosentan 2 mg/kg twice daily; treatment duration 12 weeks; FUTURE 1: n = 36, bosentan 2 mg/kg twice daily for 4 weeks followed by 4 mg/kg twice daily; treatment duration 12 weeks) was similar to that observed in the pivotal trials in adult patients with PAH. In BREATHE-3, the most frequent adverse reactions were flushing (21%), headache, and abnormal liver function test (each 16%). In FUTURE 1, the most frequent adverse reactions were infections (33%) and abdominal pain/discomfort (19%). There were no cases of liver enzyme elevations in the FUTURE 1 study.</p><p><u>Laboratory abnormalities</u></p><p><em>Liver test abnormalities</em></p><p>In the clinical programme, dose-dependent elevations in liver aminotransferases generally occurred within the first 26 weeks of treatment, usually developed gradually, and were mainly asymptomatic. In the post-marketing period rare cases of liver cirrhosis and liver failure have been reported.</p><p>The mechanism of this adverse effect is unclear. These elevations in aminotransferases may reverse spontaneously while continuing treatment with the maintenance dose of Bosentor or after dose reduction, but interruption or cessation may be necessary (see section 4.4).</p><p>In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases &ge; 3 times the upper limit of normal (ULN) were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients. Elevations to &ge; 8 &times; ULN were seen in 3.6% of the bosentan-treated patients and 0.4% of the placebo-treated patients. Elevations in aminotransferases were associated with elevated bilirubin (&ge; 2 &times; ULN) without evidence of biliary obstruction in 0.2% (5 patients) on bosentan and 0.3% (6 patients) on placebo.</p><p><em>Haemoglobin</em></p><p>A decrease in haemoglobin concentration to below 10 g/dL from baseline was reported in 8.0% of bosentan-treated patients and 3.9% of placebo-treated patients (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in <u>Appendix V</u>.</p><p>To report any side effect(s) in <strong><em>Saudi</em></strong><strong><em> Arabia</em></strong>, Please contact:</p><p><strong>&nbsp;</strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: </strong><strong>npc.drug@sfda.gov.sa</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website:</strong><strong> </strong><strong>www.sfda.gov.sa/npc</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other GCC countries: Please contact the relevant competent authority.op of the page</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bosentan has been administered as a single dose of up to 2400 mg to healthy subjects and up to 2000 mg/day for 2 months in patients with a disease other than pulmonary hypertension. The most common adverse reaction was headache of mild to moderate intensity.</p><p>&nbsp;</p><p>Massive overdose may result in pronounced hypotension requiring active cardiovascular support. In the post-marketing period there was one reported overdose of 10,000 mg of Bosentor taken by an adolescent male patient. He had symptoms of nausea, vomiting, hypotension, dizziness, sweating and blurred vision. He recovered completely within 24 hours with blood pressure support. Note: bosentan is not removed through dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antihypertensives, ATC code: C02KX01</p><p><u>Mechanism of action</u></p><p>Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ET<sub>A</sub> and ET<sub>B</sub>) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.</p><p>The neurohormone endothelin-1 (ET-1) is one of the most potent vasoconstrictors known and can also promote fibrosis, cell proliferation, cardiac hypertrophy and remodelling, and is pro-inflammatory. These effects are mediated by endothelin binding to ET<sub>A</sub> and ET<sub>B</sub> receptors located in the endothelium and vascular smooth muscle cells. ET-1 concentrations in tissues and plasma are increased in several cardiovascular disorders and connective tissue diseases, including pulmonary arterial hypertension, scleroderma, acute and chronic heart failure, myocardial ischaemia, systemic hypertension and atherosclerosis, suggesting a pathogenic role of ET-1 in these diseases. In pulmonary arterial hypertension and heart failure, in the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with the severity and prognosis of these diseases.</p><p>Bosentan competes with the binding of ET-1 and other ET peptides to both ET<sub>A</sub> and ET<sub>B</sub> receptors, with a slightly higher affinity for ET<sub>A</sub> receptors (K<sub>i</sub> = 4.1&ndash;43 nanomolar) than for ET<sub>B</sub> receptors (K<sub>i</sub> = 38&ndash;730 nanomolar). Bosentan specifically antagonises ET receptors and does not bind to other receptors.</p><p><u>Efficacy</u></p><p><em>Animal models</em></p><p>In animal models of pulmonary hypertension, chronic oral administration of bosentan reduced pulmonary vascular resistance and reversed pulmonary vascular and right ventricular hypertrophy. In an animal model of pulmonary fibrosis, bosentan reduced collagen deposition in the lungs.</p><p><em>Efficacy in adult patients with pulmonary arterial hypertension</em></p><p>Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class III&ndash;IV pulmonary arterial hypertension (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma). After 4 weeks of bosentan 62.5 mg twice daily, the maintenance doses studied in these studies were 125 mg twice daily in AC-052-351, and 125 mg twice daily and 250 mg twice daily in AC-052-352.</p><p>Bosentan was added to patients&#39; current therapy, which could include a combination of anticoagulants, vasodilators (e.g., calcium channel blockers), diuretics, oxygen and digoxin, but not epoprostenol. Control was placebo plus current therapy.</p><p>The primary endpoint for each study was change in 6-minute walk distance at 12 weeks for the first study and 16 weeks for the second study. In both studies, treatment with bosentan resulted in significant increases in exercise capacity. The placebo-corrected increases in walk distance compared to baseline were 76 metres (p = 0.02; t-test) and 44 metres (p = 0.0002; Mann-Whitney U test) at the primary endpoint of each study, respectively. The differences between the two groups, 125 mg twice daily and 250 mg twice daily, were not statistically significant but there was a trend towards improved exercise capacity in the group treated with 250 mg twice daily.</p><p>The improvement in walk distance was apparent after 4 weeks of treatment, was clearly evident after 8 weeks of treatment and was maintained for up to 28 weeks of double-blind treatment in a subset of the patient population.</p><p>In a retrospective responder analysis based on change in walking distance, WHO functional class and dyspnoea of the 95 patients randomised to bosentan 125 mg twice daily in the placebo-controlled studies, it was found that at week 8, 66 patients had improved, 22 were stable and 7 had deteriorated. Of the 22 patients stable at week 8, 6 improved at week 12/16 and 4 deteriorated compared with baseline. Of the 7 patients who deteriorated at week 8, 3 improved at week 12/16 and 4 deteriorated compared with baseline.</p><p>Invasive haemodynamic parameters were assessed in the first study only. Treatment with bosentan led to a significant increase in cardiac index associated with a significant reduction in pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.</p><p>A reduction in symptoms of pulmonary arterial hypertension was observed with bosentan treatment. Dyspnoea measurement during walk tests showed an improvement in bosentan-treated patients. In the AC-052-352 study, 92% of the 213 patients were classified at baseline as WHO functional class III and 8% as class IV. Treatment with bosentan led to a WHO functional class improvement in 42.4% of patients (placebo 30.4%). The overall change in WHO functional class during both studies was significantly better among bosentan-treated patients as compared with placebo-treated patients. Treatment with bosentan was associated with a significant reduction in the rate of clinical worsening compared with placebo at 28 weeks (10.7% vs 37.1%, respectively; p = 0.0015).</p><p>In a randomised, double-blind, multi-centre, placebo-controlled study (AC-052-364 [EARLY]), 185 PAH patients in WHO functional class II (mean baseline 6-minute walk distance of 435 metres) received bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily (n = 93), or placebo (n = 92) for 6 months. Enrolled patients were PAH-treatment-na&iuml;ve (n = 156) or on a stable dose of sildenafil (n = 29). The co-primary endpoints were percentage change from baseline in pulmonary vascular resistance (PVR) and change from baseline in 6-minute walk distance to Month 6 versus placebo. The table below illustrates the pre-specified protocol analyses.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>PVR (dyn.sec/cm<sup>5</sup>)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6-Minute Walk Distance (m)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo (n=88)</p></td><td style="vertical-align:top"><p>Bosentan (n=80)</p></td><td style="vertical-align:top"><p>Placebo (n=91)</p></td><td style="vertical-align:top"><p>Bosentan (n=86)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (BL); mean (SD)</p></td><td style="vertical-align:top"><p>802 (365)</p></td><td style="vertical-align:top"><p>851 (535)</p></td><td style="vertical-align:top"><p>431 (92)</p></td><td style="vertical-align:top"><p>443 (83)</p></td></tr><tr><td style="vertical-align:top"><p>Change from BL; mean (SD)</p></td><td style="vertical-align:top"><p>128 (465)</p></td><td style="vertical-align:top"><p>&minus;69 (475)</p></td><td style="vertical-align:top"><p>&minus;8 (79)</p></td><td style="vertical-align:top"><p>11 (74)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment effect</p></td><td colspan="2" style="vertical-align:top"><p>&minus;22.6%</p></td><td colspan="2" style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>95% CL</p></td><td colspan="2" style="vertical-align:top"><p>&minus;34, &minus;10</p></td><td colspan="2" style="vertical-align:top"><p>&minus;4, 42</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td><td colspan="2" style="vertical-align:top"><p>0.0758</p></td></tr></tbody></table><p>PVR = pulmonary vascular resistance</p><p>Treatment with bosentan was associated with a reduction in the rate of clinical worsening, defined as a composite of symptomatic progression, hospitalisation for PAH and death, compared with placebo (proportional risk reduction 77%, 95% CI 20%&ndash;94%, p = 0.0114). The treatment effect was driven by improvement in the component symptomatic progression. There was one hospitalisation related to PAH worsening in the bosentan group and three hospitalisations in the placebo group. Only one death occurred in each treatment group during the 6-month double-blind study period, therefore no conclusion can be drawn on survival.</p><p>Long-term data were generated from all 173 patients who were treated with bosentan in the controlled phase and/or were switched from placebo to bosentan in the open-label extension phase of the EARLY study. The mean duration of exposure to bosentan treatment was 3.6 &plusmn; 1.8 years (up to 6.1 years), with 73% of patients treated for at least 3 years and 62% for at least 4 years. Patients could receive additional PAH treatment as required in the open-label extension. The majority of patients were diagnosed with idiopathic or heritable pulmonary arterial hypertension (61%). Overall, 78% of patients remained in WHO functional class II. Kaplan-Meier estimates of survival were 90% and 85% at 3 and 4 years after the start of treatment, respectively. At the same timepoints, 88% and 79% of patients remained free from PAH worsening (defined as all-cause death, lung transplantation, atrial septostomy or start of intravenous or subcutaneous prostanoid treatment). The relative contributions of previous placebo treatment in the double-blind phase and of other medications started during the open-label extension period are unknown.</p><p>In a prospective, multi-centre, randomised, double-blind, placebo-controlled study (AC-052-405 [BREATHE-5]), patients with pulmonary arterial hypertension WHO functional class III and Eisenmenger physiology associated with congenital heart disease received bosentan 62.5 mg twice daily for 4 weeks, then 125 mg twice daily for a further 12 weeks (n = 37, of whom 31 had a predominantly right to left, bidirectional shunt). The primary objective was to show that bosentan did not worsen hypoxaemia. After 16 weeks, the mean oxygen saturation was increased in the bosentan group by 1.0% (95% CI &ndash;0.7%&ndash;2.8%) as compared to the placebo group (n = 17 patients), showing that bosentan did not worsen hypoxaemia. The mean pulmonary vascular resistance was significantly reduced in the bosentan group (with a predominant effect observed in the subgroup of patients with bidirectional intracardiac shunt). After 16 weeks, the mean placebo-corrected increase in 6-minute walk distance was 53 metres (p = 0.0079), reflecting improvement in exercise capacity. Twenty-six patients continued to receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5 study (mean duration of treatment = 24.4 &plusmn; 2.0 weeks) and, in general, efficacy was maintained.</p><p>An open-label, non-comparative study (AC-052-362[BREATHE-4]) was performed in 16 patients with WHO functional class III PAH associated with HIV infection. Patients were treated with bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily for a further 12 weeks. After 16 weeks&#39; treatment, there were significant improvements from baseline in exercise capacity: the mean increase in 6-minute walk distance was 91.4 metres from 332.6 metres on average at baseline (p &lt; 0.001). No formal conclusion can be drawn regarding the effects of bosentan on antiretroviral drug efficacy (see also section 4.4).</p><p>There are no studies to demonstrate beneficial effects of Bosentor treatment on survival. However, long-term vital status was recorded for all 235 patients who were treated with bosentan in the two pivotal placebo-controlled studies (AC-052-351 and AC-052-352) and/or their two uncontrolled, open-label extensions. The mean duration of exposure to bosentan was 1.9 years &plusmn; 0.7 years (min: 0.1 years; max: 3.3 years) and patients were observed for a mean of 2.0 &plusmn; 0.6 years. The majority of patients were diagnosed as primary pulmonary hypertension (72%) and were in WHO functional class III (84%). In this total population, Kaplan-Meier estimates of survival were 93% and 84% 1 and 2 years after the start of treatment with bosentan, respectively. Survival estimates were lower in the subgroup of patients with PAH secondary to systemic sclerosis. The estimates may have been influenced by the initiation of epoprostenol treatment in 43/235 patients.</p><p><em><u>Study performed in children with pulmonary arterial hypertension</u></em></p><p>One study has been conducted in children with pulmonary hypertension. Bosentan film-coated tablets were evaluated in an open-label non-controlled study in 19 paediatric patients with pulmonary arterial hypertension (AC-052-356 [BREATHE-3]: primary pulmonary hypertension, 10 patients, and pulmonary arterial hypertension related to congenital heart diseases, 9 patients). This study was primarily designed as a pharmacokinetic study (see section 5.2). Patients were divided into and dosed according to three body-weight groups for 12 weeks. Half of the patients in each group were already being treated with intravenous epoprostenol and the dose of epoprostenol remained constant for the duration of the study. The age range was 3&ndash;15 years. Patients were in WHO functional class II (n = 15 patients, 79%) or class III (n = 4 patients, 21%) at baseline.</p><p>Haemodynamics were measured in 17 patients. The mean increase from baseline in cardiac index was 0.5 L/min/m<sup>2</sup>, the mean decrease in mean pulmonary arterial pressure was 8 mmHg, and the mean decrease in PVR was 389 dyn&middot;sec&middot;cm<sup>-5</sup>. These haemodynamic improvements from baseline were similar with or without co-administration of epoprostenol. Changes in exercise test parameters at week 12 from baseline were highly variable and none were significant.</p><p><em><u>Combination with epoprostenol </u></em></p><p>The combination of bosentan and epoprostenol has been investigated in two studies: AC-052-355 (BREATHE-2) and AC-052-356 (BREATHE-3). AC-052-355 was a multi-centre, randomised, double-blind, parallel-group study of bosentan versus placebo in 33 patients with severe pulmonary arterial hypertension who were receiving concomitant epoprostenol therapy. AC-052-356 was an open-label, non-controlled study; 10 of the 19 paediatric patients were on concomitant bosentan and epoprostenol therapy during the 12-week study. The safety profile of the combination was not different from the one expected with each component and the combination therapy was well tolerated in children and adults. The clinical benefit of the combination has not been demonstrated.</p><p><em><u>Systemic sclerosis with digital ulcer disease</u></em></p><p>Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 122 (study AC-052-401 [RAPIDS-1]) and 190 (study AC-052-331 [RAPIDS-2]) adult patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a history of digital ulcers within the previous year). In study AC-052-331, patients had to have at least one digital ulcer of recent onset, and across the two studies 85% of patients had ongoing digital ulcer disease at baseline. After 4 weeks of bosentan 62.5 mg twice daily, the maintenance dose studied in both these studies was 125 mg twice daily. The duration of double-blind therapy was 16 weeks in study AC-052-401, and 24 weeks in study AC-052-331.</p><p>Background treatments for systemic sclerosis and digital ulcers were permitted if they remained constant for at least 1 month prior to the start of treatment and during the double-blind study period.</p><p>The number of new digital ulcers from baseline to study endpoint was a primary endpoint in both studies. Treatment with bosentan resulted in fewer new digital ulcers for the duration of therapy, compared with placebo. In study AC-052-401, during 16 weeks of double-blind therapy, patients in the bosentan group developed a mean of 1.4 new digital ulcers vs 2.7 new digital ulcers in the placebo group (p = 0.0042). In study AC-052-331, during 24 weeks of double-blind therapy, the corresponding figures were 1.9 vs 2.7 new digital ulcers, respectively (p = 0.0351). In both studies, patients on bosentan were less likely to develop multiple new digital ulcers during the study and took longer to develop each successive new digital ulcer than did those on placebo. The effect of bosentan on reduction of the number of new digital ulcers was more pronounced in patients with multiple digital ulcers.</p><p>No effect of bosentan on time to healing of digital ulcers was observed in either study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of bosentan have mainly been documented in healthy subjects. Limited data in patients show that the exposure to bosentan in adult pulmonary arterial hypertension patients is approximately 2-fold greater than in healthy adult subjects.</p><p>In healthy subjects, bosentan displays dose- and time-dependent pharmacokinetics. Clearance and volume of distribution decrease with increased intravenous doses and increase with time. After oral administration, the systemic exposure is proportional to dose up to 500 mg. At higher oral doses, C<sub>max</sub> and AUC increase less than proportionally to the dose.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>In healthy subjects, the absolute bioavailability of bosentan is approximately 50% and is not affected by food. The maximum plasma concentrations are attained within 3&ndash;5 hours.</p><p><u>Distribution</u></p><p>Bosentan is highly bound (&gt; 98%) to plasma proteins, mainly albumin. Bosentan does not penetrate into erythrocytes.</p><p>A volume of distribution (V<sub>ss</sub>) of about 18 litres was determined after an intravenous dose of 250 mg.</p><p><u>Biotransformation and elimination</u></p><p>After a single intravenous dose of 250 mg, the clearance was 8.2 L/h. The terminal elimination half-life (t<sub>1/2</sub>) is 5.4 hours.</p><p>Upon multiple dosing, plasma concentrations of bosentan decrease gradually to 50%&ndash;65% of those seen after single dose administration. This decrease is probably due to auto-induction of metabolising liver enzymes. Steady-state conditions are reached within 3&ndash;5 days.</p><p>Bosentan is eliminated by biliary excretion following metabolism in the liver by the cytochrome P450 isoenzymes, CYP2C9 and CYP3A4. Less than 3% of an administered oral dose is recovered in urine.</p><p>Bosentan forms three metabolites and only one of these is pharmacologically active. This metabolite is mainly excreted unchanged via the bile. In adult patients, the exposure to the active metabolite is greater than in healthy subjects. In patients with evidence of the presence of cholestasis, the exposure to the active metabolite may be increased.</p><p>Bosentan is an inducer of CYP2C9 and CYP3A4 and possibly also of CYP2C19 and the P-glycoprotein. <em>In vitro</em>, bosentan inhibits the bile salt export pump in hepatocyte cultures.</p><p><em>In vitro</em> data demonstrated that bosentan had no relevant inhibitory effect on the CYP isoenzymes tested (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, 3A4). Consequently, bosentan is not expected to increase the plasma concentrations of medicinal products metabolised by these isoenzymes.</p><p><u>Pharmacokinetics in special populations</u></p><p>Based on the investigated range of each variable, it is not expected that the pharmacokinetics of bosentan will be influenced by gender, body weight, race, or age in the adult population to any relevant extent. No pharmacokinetic data are available in children under 2 years.</p><p><em><u>Children</u></em></p><p>The pharmacokinetics of single and multiple oral doses of the film-coated tablet formulation of bosentan were studied in paediatric patients with pulmonary arterial hypertension who were dosed on the basis of body weight (see section 5.1, AC-052-356 [BREATHE-3]). The exposure to bosentan decreased with time in a manner consistent with the known auto-induction properties of bosentan. The mean AUC (CV%) values of bosentan in paediatric patients treated with 31.25, 62.5 or 125 mg twice daily were 3,496 (49), 5,428 (79), and 6,124 (27) ng&middot;h/mL, respectively, and were lower than the value of 8,149 (47) ng&middot;h/mL observed in adult patients with pulmonary arterial hypertension receiving 125 mg twice daily. At steady state, the systemic exposures in paediatric patients weighing 10&ndash;20 kg, 20&ndash;40 kg and &gt; 40 kg were 43%, 67% and 75%, respectively, of the adult systemic exposure.</p><p>In a second pharmacokinetic study (AC-052-365 [FUTURE 1]), 36 paediatric patients aged 2&ndash;11 years with PAH were treated at 2 and 4 mg/kg twice daily with the dispersible tablet. No dose proportionality was observed. Steady-state bosentan plasma concentrations were similar at oral doses of 2 and 4 mg/kg. The AUC<sub>&tau;</sub> was 3,577 ng&middot;h/mL for 2 mg/kg twice daily and 3,371 ng&middot;h/mL for 4 mg/kg twice daily.The average exposure to bosentan in paediatric patients was about half the exposure in adult patients at the 125 mg twice daily maintenance dose but showed a large overlap with the exposures in adults. Based on the findings in studies BREATHE-3 and FUTURE 1, it appears that the exposure to bosentan reaches a plateau at lower doses in paediatric patients than in adults, and that doses higher than 2 mg/kg twice daily will not result in greater exposure to bosentan in paediatric patients.</p><p>The consequences of these findings regarding hepatotoxicity are unknown. Gender and the concomitant use of intravenous epoprostenol had no significant effect on the pharmacokinetics of bosentan.</p><p><em><u>Hepatic impairment</u></em></p><p>In patients with mildly impaired liver function (Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed. The steady-state AUC of bosentan was 9% higher and the AUC of the active metabolite, Ro 48-5033, was 33% higher in patients with mild hepatic impairment than in healthy volunteers.</p><p>The impact of moderately impaired liver function (Child-Pugh class B) on the pharmacokinetics of bosentan and its primary metabolite Ro 48-5033 was investigated in a study including 5 patients with pulmonary hypertension associated with portal hypertension and Child-Pugh class B hepatic impairment, and 3 patients with pulmonary arterial hypertension from other causes and normal liver function. In the patients with Child-Pugh class B liver impairment, the mean (95% CI) steady-state AUC of bosentan was 360 (212-613) ng.h/mL, i.e., 4.7 times higher, and the mean (95% CI) AUC of the active metabolite Ro 48-5033 was 106 (58.4-192) ng.h/mL, i.e., 12.4 times higher than in the patients with normal liver function (bosentan: mean [95% CI] AUC : 76.1 [9.07-638] ng.h/mL; Ro 48-5033: mean [95% CI] AUC 8.57 [1.28-57.2] ng.h/ml). Though the number of patients included was limited and with high variability, these data indicate a marked increase in the exposure to bosentan and its primary metabolite Ro 48-5033 in patients with moderate liver function impairment (Child-Pugh class B).</p><p>The pharmacokinetics of bosentan have not been studied in patients with Child-Pugh class C hepatic impairment. Bosentor is contra-indicated in patients with moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 4.3).</p><p><em><u>Renal impairment</u></em></p><p>In patients with severe renal impairment (creatinine clearance 15&ndash;30 mL/min), plasma concentrations of bosentan decreased by approximately 10%. Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared to subjects with normal renal function. No dose adjustment is required in patients with renal impairment. There is no specific clinical experience in patients undergoing dialysis. Based on physicochemical properties and the high degree of protein binding, bosentan is not expected to be removed from the circulation by dialysis to any significant extent (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A 2-year carcinogenicity study in mice showed an increased combined incidence of hepatocellular adenomas and carcinomas in males, but not in females, at plasma concentrations about 2 to 4 times the plasma concentrations achieved at the therapeutic dose in humans. In rats, oral administration of bosentan for 2 years produced a small, significant increase in the combined incidence of thyroid follicular cell adenomas and carcinomas in males, but not in females, at plasma concentrations about 9 to 14 times the plasma concentrations achieved at the therapeutic dose in humans. Bosentan was negative in tests for genotoxicity. There was evidence of a mild thyroid hormonal imbalance induced by bosentan in rats. However, there was no evidence of bosentan affecting thyroid function (thyroxine, TSH) in humans.</p><p>The effect of bosentan on mitochondrial function is unknown.</p><p>Bosentan has been shown to be teratogenic in rats at plasma levels higher than 1.5 times the plasma concentrations achieved at the therapeutic dose in humans. Teratogenic effects, including malformations of the head and face and of the major vessels, were dose dependent. The similarities of the pattern of malformations observed with other ET receptor antagonists and in ET knock-out mice indicate a class effect. Appropriate precautions must be taken for women of child-bearing potential (see sections 4.3, 4.4 and 4.6).</p><p>In fertility studies in male and female rats at plasma concentrations 21 and 43 times, respectively, the expected therapeutic level in humans, no effects on sperm count, motility and viability, or on mating performance or fertility were observed, nor was there any adverse effect on the development of the pre-implantation embryo or on implantation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients with known effect: Not Applicable</p><p>&nbsp;</p><p>Bosentor 125 mg Film coated tablets contains the following inactive ingredients:</p><p><u>Tablet core:</u></p><p>Pregelatinised starch</p><p>Sodium starch glycollate</p><p>Povidone</p><p>Magnesium stearate</p><p><u>Film coat:</u></p><p>Hydroxypropyl methylcellulose</p><p>Iron oxide red</p><p>Iron oxide yellow</p><p>Titanium dioxide</p><p>Triacetin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="3" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Do not store above 30 &deg;C.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Supplied in blisters of 60 tablets</p><p>Blisters: White Tekniflex VA 7300 with Aluminium foil 25 microns push through,</p><p>Carton contains 4 blisters x15&rsquo;s tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharma Pharmaceutical Industry, Saudi Arabia
Second Industrial Zone, Riyadh, Saudi Arabia.
www.pharma.com.sa
Email: info@pharma.com.sa
Manufacturer:
Genvion Corporation for Pharmascience Inc. 
500 Camiel System street, Winnipeg, Mannitoba, R2J 4K2, Winnipeg, Canada.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>